David Dai is ranked #1942 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

David Dai (UBS) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are David Dai's stock ratings?

About 46% of David's ratings were profitable over a one-year hold, with an average return of -5.0% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/David Dai

UBS

David Dai

UBS

Wall Street Analyst

★★☆☆☆

#1942

on 13Foresight · ranked by our own returns

46%

Success Rate

-3.7%

Average Return

13 of 28 calls profitable · -9.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 46% of David Dai's ratings turned a profit when each position was held for 1 year — averaging -3.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

53 Buy 14 Hold 0 Sell

David's Stock Coverage 29 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
CLDX Celldex	Jun 16, 2026	BUY	Strong Buy +20.6% avg upside 28 analysts	$45.00 38.69% Upside	+0.0%
NUVL Nuvalent	Jun 10, 2026	HOLD	Buy -0.3% avg upside 21 analysts	$124.00 0.39% Upside	+0.0%
CGEM Cullinan Management	Jun 08, 2026	BUY	Strong Buy +125.7% avg upside 15 analysts	$24.00 59.74% Upside	+8.7%
NBTX Nanobiotix	Jun 04, 2026	HOLD	Strong Buy -7.3% avg upside 5 analysts	$30.00 17.38% Downside	-3.9%
KURA Kura Oncology	Jun 03, 2026	BUY	Strong Buy +162.8% avg upside 26 analysts	$15.00 51.11% Upside	+10.6%
BNTX BioNTech SE	May 27, 2026	BUY	Strong Buy +50.5% avg upside 26 analysts	$135.00 48.56% Upside	-2.3%
ENGN enGene Holdings	May 14, 2026	HOLD	Buy +478.3% avg upside 13 analysts	$2.00 16.38% Upside	-3.3%
SNDX Syndax Pharmaceuticals	May 13, 2026	BUY	Strong Buy +88.7% avg upside 27 analysts	$37.00 94.68% Upside	-12.3%
CGON CG Oncology, Inc.	May 08, 2026	BUY	Strong Buy +41.1% avg upside 17 analysts	$90.00 47.37% Upside	-12.3%
JANX Janux Therapeutics Inc	Apr 15, 2026	HOLD	Strong Buy +217.9% avg upside 21 analysts	$15.00 5.50% Upside	-5.9%
AU:TLX Telix Pharmaceuticals	Apr 08, 2026	BUY	Strong Buy +75.9% avg upside 13 analysts	$31.00 113.70% Upside	·
JSPR Jasper Therapeutics	Apr 02, 2026	HOLD	Strong Buy +6345.3% avg upside 17 analysts	$1.50 231.12% Upside	-31.5%
CATX Perspective Therapeutics	Mar 18, 2026	BUY	Strong Buy +278.9% avg upside 22 analysts	$8.00 171.12% Upside	-39.7%
IOVA Iovance Biotherapeutics	Mar 05, 2026	HOLD	Strong Buy +225.4% avg upside 24 analysts	$4.00 2.35% Upside	-24.7%
KYMR Kymera Therapeutics	Mar 03, 2026	BUY	Strong Buy +9.0% avg upside 36 analysts	$128.00 41.61% Upside	+4.1%
MRNA Moderna	Jan 07, 2026	HOLD	Hold +6.4% avg upside 38 analysts	$34.00 46.87% Downside	+78.2%
NRIX Nurix Therapeutics	Nov 10, 2025	BUY	Strong Buy +76.3% avg upside 26 analysts	$23.00 31.09% Upside	+43.5%
SMMT Summit Therapeutics	Nov 10, 2025	BUY	Strong Buy +112.6% avg upside 27 analysts	$33.00 139.94% Upside	-24.2%
VRTX Vertex Pharmaceuticals	Nov 07, 2025	BUY	Strong Buy -2.7% avg upside 61 analysts	$546.00 20.99% Upside	+12.1%
GILD Gilead Sciences	Oct 31, 2025	HOLD	Strong Buy -4.8% avg upside 66 analysts	$112.00 9.55% Downside	+5.3%
IDYA IDEAYA Biosciences	Oct 24, 2025	BUY	Strong Buy +55.3% avg upside 29 analysts	$50.00 60.19% Upside	+7.1%
JP:6525 Kokusai Electric Corporation	Apr 02, 2025	HOLD	Strong Buy -34.9% avg upside 7 analysts	$2690.00 73.57% Downside	·
JP:8035 Tokyo Electron	Feb 26, 2025	BUY	Strong Buy -38.9% avg upside 9 analysts	$34600.00 54.07% Downside	·
JP:6758 Sony	Jan 15, 2025	BUY	Strong Buy +46.4% avg upside 14 analysts	$3900.00 24.21% Upside	·
AGEN Agenus	Sep 29, 2022	BUY	Strong Buy +165.3% avg upside 17 analysts	$5.00 66.63% Upside	-44.1%
MGNX MacroGenics	Jul 18, 2022	HOLD	Buy +326.4% avg upside 25 analysts	$5.00 20.97% Upside	+44.6%
NKTX Nkarta	May 16, 2022	BUY	Strong Buy +554.9% avg upside 15 analysts	$40.00 1298.70% Upside	-67.6%
XNCR Xencor	May 09, 2022	BUY	Strong Buy +159.5% avg upside 27 analysts	$54.00 327.15% Upside	+8.8%
ACET Adicet Bio	Mar 30, 2022	BUY	Strong Buy +212.8% avg upside 14 analysts	$28.00 245.77% Upside	-70.2%

🔒 24 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

David Dai — Frequently Asked Questions

How accurate are David Dai's stock ratings?

Based on the calls 13Foresight could measure, about 46% of David's ratings were profitable over a one-year hold, with an average return of -5.0% per rating, or -11.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is David ranked on 13Foresight?

David Dai is currently ranked #1942 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does David cover?

David most recently has ratings on CLDX, NUVL, CGEM, NBTX, KURA, BNTX, ENGN, SNDX, CGON, JANX, AU:TLX, JSPR and 17 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!